# The comparative effectiveness and safety of biologic therapies for uncontrolled severe asthma: a systematic review and network meta-analysis

Tyler Pitre
*Department of Medicine*
*McMaster University, Hamilton, ON*

Tanvir Jassal (tanvirjassal@hotmail.com)
*Department of Anesthesia*
*McMaster University, Hamilton, ON*

Albi Angjeli (angjelia@mcmaster.ca)
*Faculty of Health Sciences*
*McMaster University, Hamilton, ON*

Vineeth Jarabana (vineethjarabana@gmail.com)f
*Faculty of Health Sciences*
*Queens University, Hamilton, ON*

Sricherry Nannapaneni (sricherrynannapaneni@gmail.com)
*Faculty of Health Sciences*
*McMaster University, Hamilton, ON*

Ayesha Umair (umaira1@mcmaster.ca)
*Faculty of Health Sciences*
*McMaster University, Hamilton, ON*

Muizz Hussain (muizz.hussain@medportal.ca)
*Michael G. DeGroote School of Medicine*
*McMaster University, Hamilton, ON*

Gareth Leung (gareth.k.leung@gmail.com)
*Faculty of Medicine,*
*University of Ottawa, Ottawa, ON*

Sarah Kirsch (sarahkirsh@hotmail.com)
*Department of Anesthesia*
*McMaster University, Hamilton, ON*

Johnny Su (johnny.su@medportal.ca)
*Department of Medicine*
*McMaster University, Hamilton, ON*

Kairavi Desai (kairavi.desai@medportal.ca)
*Michael G. DeGroote School of Medicine*
*McMaster University, Hamilton, ON*

Dena Zeraatkar*
*Department of Health Research Methods, Evidence, and Impact*
*McMaster University, Hamilton, ON*

*Corresponding author: dena.zera@gmail.com; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON

**Running head:** Biologics for asthma

**Disclaimers/Conflicts of interest:** None

**Funding**: DZ is funded by a Banting postdoctoral fellowship.

**Data:** Data will be available on OSF upon publication.

**Acknowledgements:** None

**Authors' Contributions:** TP and DZ conceived the study. TJ, AA, VJ, SN, AU, MH, GL, SK, JS, KD, and TP screened and extracted data. DZ and TP performed the analysis and GRADED the certainty of the evidence. TP drafted the manuscript and all authors reviewed and provided intellectual input.

**Keywords:** asthma, biologics, systematic review, network meta-analysis

**Word count:** 3,606

**Abstract**

**Background:** To date, no trial has directly compared biologics for the treatment of uncontrolled severe asthma and the choice of biologic has been largely guided by biological and practical considerations, such as inflammatory biomarkers, blood and sputum eosinophils, and access and payer coverage.

**Study design:** Systematic review and network meta-analysis

**Methods:** We searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to May 31, 2022 for randomized trials addressing biologic therapies for asthma. Reviewers worked independently and in duplicate to screen references, extract data, and assess risk of bias. We performed a frequentist network meta-analysis and assessed the certainty (quality) of evidence using the GRADE approach. We present data as absolute risk difference per 1000 patients with 95% confidence intervals (95% CI) and continuous outcomes as mean difference (MD) and 95% CI.

**Results:** We identified 63 eligible trials, including 26,320 patients. For patients with eosinophilic asthma, tezepelumab (329 fewer exacerbations per 1000 [95% CI 272.6 to 366.6 fewer]) and dupilumab (319.6 fewer exacerbations per 1000 [95% CI 272.6 to 357.2 fewer]) reduce exacerbations compared to placebo (high certainty). Tezepelumab (MD 0.24 L [95% CI 0.16 to 0.32]) and dupilumab (0.25 L (95% CI 0.21 to 0.29) improve lung function (FEV1) compared to placebo (high certainty). Both tezepelumab (110.97 fewer hospital admissions per 1000 (95% CI 94.53 to 120.56 fewer) and dupilumab (97.27 fewer hospitalizations [4.11 to 124.67 fewer]) probably reduce hospital admissions compared to placebo (moderate certainty). For patients with low eosinophils, biologics probably do not improve asthma outcomes. For these patients, tezepelumab (MD 0.1 L [95% CI 0 to 0.19]) and dupilumab (MD 0.1 L [95% CI 0 to 0.20)] may improve lung function (low certainty). None of the biologics increased adverse events leading to discontinuation (high certainty).

**Conclusion:** For patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing exacerbations, without important differences in the effects of these biologics. For patients with low eosinophils, however, biologics, including tezepelumab, probably do not prevent exacerbations, improve asthma control, or lung function.

## Background

Asthma is a respiratory condition that affects an estimated 300 million people and is associated with significant morbidity (1). Patients whose asthma cannot be controlled by inhaled corticosteroids and long-acting β2-agonists and patients who rely on oral corticosteroids may benefit from biologics (2). Biologics target the signalling pathways involved in inflammation, which play an important role in the pathogenesis of asthma.

To date, no trial has directly compared biologics for the treatment of uncontrolled severe asthma and the choice of biologic has been largely guided by biological and practical considerations, such as inflammatory biomarkers, blood and sputum eosinophils, and access and payer coverage. Additionally, the optimal biologic for patients who qualify for more than one option and the order in which clinicians should trial biologics for patients are unclear (3). Furthermore, access to most biologics has been limited to patients with specific phenotypes (e.g., high eosinophilic asthma). The emergence of anti-alarmins—treatments that should theoretically be effective regardless of eosinophil levels—further necessitates additional evidence to help select optimal biologics for patients (4).

To address these challenges, we present a systematic review and network meta-analysis comparing biologics for severe uncontrolled asthma. A network meta-analysis pools results across two or more studies and, unlike a traditional pairwise meta-analysis, facilitates comparisons of three or more interventions simultaneously (5). A network meta-analysis can also yield more precise estimates than a traditional pairwise meta-analysis and can facilitate comparison of interventions that have not been directly compared against each other.

## Methods

We registered our protocol on Open Science Framework (https://osf.io/m29du/) on June 14, 2022. We report our results using the PRISMA-NMA extension (6).

### *Search strategy*

In consultation with an experienced research librarian, we searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to May 31, 2022, for randomized trials addressing biologic therapies for asthma. We did not restrict the search by language or date of publication. We supplemented our search by reviewing references of similar systematic reviews (7-11). Supplement 1 presents our full search strategy.

122 ***Screening***

123 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working
124 independently and in duplicate, reviewed titles and abstracts of search results and subsequently the full-
125 texts of records deemed potentially eligible at the title and abstract screening stage.

126 We included trials that randomized adults with severe asthma to one or more biologic therapies with
127 standard care, placebo, or other biologic therapies, regardless of language or date of publication. We
128 included trials that recruited both children and adults if 80% or more patients were adults (>18 years).
129 We excluded trials that reported on the effects of aerosolized or nebulized biologics or trials that
130 included fewer than 10 participants in each arm.

131 Reviewers resolved discrepancies by discussion, or, when necessary, by adjudication with a third party.

132 ***Data extraction***

133 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working
134 independently and in duplicate, extracted data from eligible studies. We extracted data on trial
135 characteristics (e.g., country of recruitment), patient characteristics (e.g., age, eosinophil levels),
136 intervention characteristics (e.g., dose and duration), and outcomes. The coreASTHMA core outcome
137 set—a multistakeholder core outcome set for asthma—informed our outcomes of interest (12), which
138 include exacerbations, asthma control as measured by the Asthma Control Questionnaire, lung function
139 measured by prebronchodilator forced expiratory volume in 1 second (FEV1), hospitalizations, reduction
140 in use of systemic corticosteroids by ≥50%, and adverse events leading to discontinuation.

141 We anticipated that the effects of biologics on exacerbations, asthma control, and lung function may
142 differ according to baseline eosinophil count. To facilitate subgroup analyses, we extracted subgroup
143 data based on baseline blood and sputum eosinophil count, when reported. We classified trials as
144 reporting on eosinophilic asthma when 80% or more of patients had blood eosinophils of ≥300
145 eosinophils per µL in the past year, ≥150 eosinophils per µL in the trial screening period, or sputum
146 eosinophils ≥3%.

147 Reviewers resolved discrepancies by discussion or, when necessary, by adjudication with a third party.

148 ***Risk of bias assessments***

149 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working
150 independently and in duplicate, assessed the risk of bias of trials using a modification of the Cochrane-
151 endorsed RoB 2.0 tool (13, 14). We rated each outcome as either at (1) low risk of bias, (2) probably low

risk of bias, (3) probably high risk of bias or (4) high risk of bias, across the following domains: bias arising from the randomisation process; bias owing to departures from the intended intervention; bias from missing outcome data; bias in measurement of the outcome; bias in selection of the reported results. Trials were rated at high risk of bias overall if one or more domains were rated at probably high or high risk of bias. Reviewers resolved discrepancies by discussion and, when not possible, with adjudication by a third party. Supplement 2 presents the modified risk of bias tool.

***Data analysis***

We present the results of dichotomous outcomes as relative risks (RRs) and continuous outcomes as mean differences (MDs), with associated 95% confidence intervals (95% CIs). To facilitate interpretation, for dichotomous outcomes, we calculate absolute effects expressed as events per 1,000 patients, using the median risk in the placebo arms as the assumed baseline risk without biologics.

For each outcome, we performed frequentist random-effects network meta-analysis using the restricted maximum likelihood (REML) estimator. We categorized each biologic drug as a separate node in the network. We anticipated that the effects of biologic therapies on exacerbations, asthma control, and lung function may differ based on baseline eosinophil count. For these outcomes, we performed three analyses: one restricted to patients with high eosinophils, one restricted to patients with low eosinophils, and one including all patients.

We summarize heterogeneity using the $I^2$ statistic. We considered heterogeneity ranging from 0%–40% as potentially unimportant, 30%–60% as moderate, 50%–90% as substantial and 75%–100% as critical (15). We used the node-splitting method to test for local incoherence (difference between direct and indirect evidence in closed loops) (16). For analyses with 10 or more trials, we assessed for publication bias using comparison-adjusted funnel plots and the Egger's test (17).

We performed meta-analyses using meta and netmeta packages in R v. 4.1.2 (Vienna, Austria) and we used the networkplot command in Stata v.17 (StataCorp) to generate network plots (18-20).

***Evaluation of the certainty (quality) of evidence***

Reviewers, working independently and in duplicate, assessed the certainty (quality) of evidence using the GRADE approach for network meta-analysis (21-23). Reviewers resolved discrepancies by discussion or by adjudication by a third reviewer.

For each comparison and for each outcome, we rated the certainty of evidence as either high, moderate, low, or very low based on considerations of risk of bias (i.e., study limitations), inconsistency

182 (i.e., heterogeneity in trial results), indirectness (i.e., differences between the questions addressed in
183 trials and the question of interest), publication bias (i.e., the tendency for trials with statistically
184 significant results or positive results to be published, published faster, or published in journals with
185 higher visibility), intransitivity (i.e., differences in trial characteristics across the network), incoherence
186 (i.e., difference between direct and indirect effects), and imprecision (i.e., random error). High certainty
187 evidence indicates situations in which we are confident that the estimated effect represents the true
188 effect and low or very low certainty evidence indicates situations in which the estimated effect may be
189 substantially different from the true effect.

190 We made judgements about imprecision using the minimally contextualized GRADE approach (23). This
191 approach does not consider statistical significance as the only indicator of whether an intervention is
192 effective. An estimate may not be statistically significant but may still have evidence of moderate
193 certainty for benefit or harm, depending on the width of the confidence intervals and whether they
194 cross the thresholds of clinical significance. Conversely, an intervention may produce results that are
195 statistically significant but that indicate no important benefit or harm (e.g., a 10 mL change in FEV1). A
196 minimally contextualized approach considers whether confidence intervals include the minimally
197 important difference (the smallest change in the outcome considered to be important to patients) and
198 does not consider whether it includes both minimally important and large effects.

199 We sourced minimally important differences from the literature or by consensus of the authors. We
200 considered a 20% reduction in risk of exacerbations (24, 25), 0.5 reduction in the Asthma Control
201 Questionnaire (25), 100 mL reduction in FEV1 (24, 26), 5% reduction in risk of hospital admissions, 20%
202 increase in risk of reducing oral corticosteroids by ≥50%, and a 10% increase in risk of adverse events
203 leading to discontinuation to be minimally important.

204 We report our results using guidance from the GRADE Working Group, which involves describing the
205 effect of an intervention based on the certainty of evidence (i.e., high certainty evidence the drug is
206 effective, moderate certainty evidence the drug is probably effective, low certainty evidence the drug
207 may be effective and very low certainty evidence the effect of the drug is unclear) (27).

208 **Results**

209 ***Search results***

210 Our search yielded 3,225 unique references. We identified a total of 57 eligible publications reporting on
211 63 unique trials with 26,320 patients (28-81). All trials were published in peer-reviewed journals in
212 English. Supplement 3 presents additional details related to study selection.

213 ***Trial and participant characteristics***

214 Table 1 presents trial and participant characteristics. Sixteen trials (4,730 patients) reported on
215 omalizumab, eight (4,511 patients) on fevipiprant, seven (2,511 patients) on reslizumab, six (1,966
216 patients) on mepolizumab, four (2,312 patients) on tralokinumab, four (1,799 patients) on tezepelumab,
217 three (1,090 patients) on dupilumab, three (1,417 patients) on benralizumab, one (375 patients) on
218 astegolimab, and one (296 patients) on itepekimab.

219 Trials typically recruited adult asthmatic patients with a history of one or more exacerbations in the last
220 year despite treatment with medium-dose to high-dose inhaled corticosteroids and another asthma
221 controller (e.g., oral corticosteroids, long-acting β2-agonists).

222 Twelve trials (3,870 patients) recruited patients with high eosinophils (blood eosinophils of ≥300
223 eosinophils per µL in the past year, ≥150 eosinophils per µL in the trial screening period, or sputum
224 eosinophils ≥3%) and 51 trials (22,432 patients) recruited patients with both low and high eosinophils.
225 Among trials that recruited patients with both low and high eosinophils, 19 (13,592 patients) reported
226 subgroup analyses based on eosinophil levels for one or more of our outcomes of interest.

227 ***Risk of bias***

228 Supplement 4 presents risk of bias assessments. We judged two trials to be at high risk of bias due to
229 their open-label design and inadequate description of allocation concealment. We judged all other
230 outcomes to be at low risk of bias. Pharmaceutical companies funded all trials.

231 ***Exacerbations***

232 Table 2 and supplement 5 present results with associated GRADE ratings. Forty-two trials, including
233 20,964 patients, reported exacerbations. Of these, twenty-seven trials reported on 10,159 patients with
234 high eosinophils and thirteen trials reported 4,628 patients with low eosinophils. Figure 1 presents the
235 geometry of the networks and figure 2 presents the network forest plot.

236 For patients with eosinophilic asthma (>=300 cells/uL), we found moderate to high certainty evidence
237 that benralizumab (RR 0.51 [95% CI 0.41 to 0.63]), dupilumab (RR 0.32 [95% 0.24 to 0.42,]) mepolizumab

238 (RR 0.52 [95% CI 0.43 to 0.64]), reslizumab (RR 0.51 [95% CI 0.4 to 0.65]), and tezepelumab (RR 0.3 [0.22
239 to 0.42]) probably reduce exacerbations compared to placebo. We did not find moderate or high
240 certainty evidence that either of these drugs are superior to each other.

241 For patients with low eosinophils (< 300 cells/uL), we did not find moderate or high certainty evidence
242 that any of the drugs reduce exacerbations (i.e., none met the pre-specified minimally important
243 difference of 20%).

244 For all patients, omalizumab, astegolimab, and tralokinumab probably do not reduce exacerbations as
245 compared to placebo.

246 Supplement 6 and 7 presents the network geometries, forest plots, and heterogeneity statistics.

247 ***Asthma control (Asthma Control Questionnaire)***

248 Thirty-six trials, including 12,161 patients, reported on asthma control using the asthma control
249 questionnaire (82). Of these, ten trials reported on 8,212 patients with high eosinophils and eight trials
250 reported on 1,905 patients with low eosinophils. Supplement 6 and 7 presents the network geometries,
251 forest plots, and heterogeneity statistics.

252 For patients with eosinophilic asthma, we found low certainty evidence that dupilumab may improve
253 asthma control compared to placebo (MD -0.73 [95% CI -0.98 to -0.48]). We did not find moderate or
254 high certainty evidence that any of the biologics improve asthma control for this population.

255 For patients with low eosinophils, we found moderate to high certainty evidence that benralizumab (MD
256 -0.23 [95% CI -0.41 to -0.06]), dupilumab (MD -0.2 [95% -0.42 to 0.02]), reslizumab (MD 0.12 [95% CI -
257 0.09 to 0.33]), and tezepelumab (MD -0.23 [95% CI -0.36 to -0.09]) probably do not improve asthma
258 control compared to placebo.

259 ***Lung function (FEV1)***

260 Forty-two trials, including 17,965 patients, reported lung function. Of these, twenty-nine trials reported
261 on 9,242 patients with high eosinophils and twelve trials reported on 2745 patients with low
262 eosinophils. Supplement 6 and 7 presents the network geometries, forest plots, and heterogeneity
263 statistics.

264 For patients with high eosinophils, we found moderate to high certainty evidence that dupilumab (MD
265 0.25 L [95% CI 0.21 to 0.29]), reslizumab (MD 0.19 L [95% CI 0.12 to 0.25]), and tezepelumab (MD 0.24 L
266 [0.16 to 0.32]) probably improve lung function compared to placebo. We found moderate certainty

evidence that dupilumab is probably superior to benralizumab (MD 0.11 L [95% CI 0.05 to 0.16]) and mepolizumab (MD 0.15 L [95% CI 0.08 to 0.22]) for improving lung function and that tezepelumab is probably superior to mepolizumab (MD 0.15 L [95% CI 0.05 to 0.24]). We found moderate certainty evidence that dupilumab and tezepelumab probably improve lung function equally well (MD 0.01 L [95% CI -0.08 to 0.1]).

For patients with low eosinophils, we did not find moderate or high certainty evidence that any biologics improve lung function.

***Hospital admissions***

Thirteen trials, including 3,113 patients, reported on hospital admission. Supplement 6 and 7 presents the network geometry, forest plot, and heterogeneity statistics.

We found moderate certainty evidence that mepolizumab (RR 0.29 [95% CI 0.09 to 0.97]), omalizumab (RR 0.38 [95% CI 0.23 to 0.65]), and tezepelumab (RR 0.19 [95% CI [0.12 to 0.31]) probably reduce hospital admissions compared to placebo. We found moderate to high certainty evidence that omalizumab is probably superior to benralizumab (RR 0.44 [95% CI 0.25 to 0.78]) and tralokinumab (RR 0.5 [95% CI 0.27 to 0.95]) for reducing hospital admissions. We found moderate certainty evidence that tezepelumab is probably superior to benralizumab for reducing hospitalizations (RR 0.22 [95% CI 0.13 to 0.37]).

***Reduction in use of oral corticosteroids (≥50% reduction in oral corticosteroids)***

Six trials, including 4849 patients, reported ≥50% reduction in oral corticosteroids. Supplement 6 and 7 presents the network geometry, forest plots, and heterogeneity statistics.

We found moderate certainty evidence that benralizumab (RR 1.77 [95% CI 1.29 to 2.43]), dupilumab (RR 1.49 [95% CI 1.22 to 1.83], and mepolizumab [RR 1.61 [95% CI 1.07 to 2.41]) probably reduce use of oral corticosteroids compared to placebo. We did not find moderate or high certainty evidence that either of these drugs are superior to each other.

***Adverse events leading to discontinuation***

Forty-seven trials, including 8,781 patients, reported adverse events leading to discontinuation. Supplement 6 and 7 presents the network geometry, forest plots, and heterogeneity statistics.

We have moderate to high certainty evidence that benralizumab (RR 1.65 [95% CI 0.79 to 3.45]), dupilumab (RR 1.03 [95% CI 0.46 to 2.3]), fevipiprant (RR 1.01 [95% CI 0.65 to 1.57]), mepolizumab [RR

296 0.65 [95% CI 0.36 to 1.16]), omalizumab (RR 1.2 [95% CI 0.80 to 1.81]), reslizumab (RR 0.65 [0.41 to
297 1.02]), tezepelumab (RR 0.68 [95% CI 0.0.34 to 1.35]), and tralokinumab (RR 2.7 [95% CI 1.45 to 5])
298 probably do not increase the risk adverse events compared to placebo.

299 **Discussion**

300 ***Main findings***

301 Our systematic review and network meta-analysis presents data from 63 trials addressing the
302 effectiveness and safety of biologics for uncontrolled severe asthma. We show that for patients with
303 eosinophilic asthma, tezepelumab and dupilumab are the most effective at reducing asthma
304 exacerbations and lung function. We did not find moderate or high certainty evidence that either of
305 these drugs are superior to each other.

306 Contrary to expectations, for patients with low eosinophils, biologics, including tezepelumab that has
307 been marketed as effective even in patients with low eosinophils (83), probably do not prevent
308 exacerbations or improve asthma control or lung function.

309 ***Strengths and limitation***

310 The strengths of this review include our comprehensive search for trials addressing biologics for asthma,
311 duplicate screening and data extraction, and rigorous evaluation of the certainty of evidence. We
312 considered the potential differential effects of biologics based on eosinophil counts, which play a key
313 role in the pathogenesis of severe asthma. We focused on patient-important outcomes and our choice
314 of outcomes was guided by a core outcome set developed by stakeholders including patients (12). We
315 apply rigorous methods for assessing the certainty of evidence from network meta-analyses using a
316 minimally contextualized approach and minimally important differences (23). Our systematic review and
317 network meta-analysis presents the only available evidence on the comparative effectiveness of
318 biologics—given the absence of trials directly comparing biologics.

319 Although we performed a rigorous search for eligible studies and supplemented our search with
320 previous systematic reviews of biologics for asthma, it is possible that we missed eligible trials.

321 While the GRADE framework presents a transparent system for assessing the certainty of evidence and
322 accounts for all factors that may bear on the certainty of evidence, its application is subjective and
323 others rating the certainty of evidence may come to different conclusions. Further, our assessment of
324 the certainty of evidence using the minimally contextualized approach required us to identify the
325 minimally important difference. We encourage evidence users to consider effects that their patients

326 would consider to be important when interpreting our results. For example, some patients may place a
327 high value on reductions in exacerbations and may consider a reduction in exacerbations less than 20%
328 to still be important.

329 In our network meta-analysis, we categorized different doses of the same biologic and different routes
330 of administration (i.e., subcutaneous vs. intravenous) in the same node. While this approach maximized
331 the number of patients included in each node, the effects of biologics may vary by dose and route of
332 administration. Most trials, however, that tested different doses and routes of administration did not
333 find evidence of clinically important differences in effects (54, 77).

334 Trials reported data on the effects of biologics between 12 and 52 weeks. The effects of biologics,
335 including potential adverse events, beyond these timeframes are uncertain.

336 We report data on adverse events that led to discontinuation. While we found biologics to be well
337 tolerated, serious and life-threatening adverse events are possible and were not captured by our review.
338 A very small proportion of patients, for example, may experience anaphylaxis—typically after the first
339 three doses. Because of this risk, clinicians should consider providing patients with epinephrine and
340 administering the first doses in a healthcare setting.

341 We present convincing evidence that the effects of biologics vary based on eosinophils. We show that
342 biologics, including tezepelumab, are probably not effective for patients with low eosinophils—a finding
343 that is consistent with a previous systematic review and network meta-analysis (9). There is also
344 inherent variability in eosinophils over time. It is possible that trials may capture patients at a random
345 high or low in eosinophil count. Therefore, our review may underestimate differences in effects of
346 biologics based on eosinophils.

347 Our review focuses on adults and includes limited data on the effects of biologics in children. Given the
348 effectiveness of these drugs in adults with eosinophilic asthma, additional clinical trials in children are
349 warranted. Currently, omalizumab—which we found to not be effective—is the only biologic approved
350 by the FDA for children under 6 years (84).

351 ***Implications***

352 Our results have implications for the management of patients with severe uncontrolled asthma. Our
353 results strongly support the use of biologics for the treatment of patients with high eosinophils. For
354 patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing exacerbations,
355 without important differences in the effects of the two biologics.

356 Our results, however, do not support the use of biologics for patients with low eosinophils. In December
357 2021, the FDA approved tezepelumab for patients with severe uncontrolled asthma, regardless of
358 eosinophil levels (83). Tezepelumab is regarded as the first biologic to reduce asthma exacerbations
359 consistently and significantly in a broad population of asthma patients. For patients with low
360 eosinophils, tezepelumab, however, did now show evidence of effectiveness. Differences between our
361 findings and findings reported in previous clinical trials may be due to our use of absolute effects and
362 minimally important differences to interpret results and the trials' emphasis on statistical significance
363 (73, 77). Suboptimal response in patients with low eosinophils may be related to multiple problematic
364 inflammatory pathways including inflammation, airflow obstruction related to airway remodeling, or
365 significant airways hyperresponsiveness. Other investigators have also been skeptical of the effects of
366 tezepelumab in patients with low eosinophils (85).

367 Our results suggest that clinicians should be mindful when using tezepelumab in patients with low
368 eosinophils given the costs and practical burdens of the drug (i.e., subcutaneous injection) and since
369 these patients are unlikely to derive as substantial of a benefit as patients with eosinophilic asthma.

370 Our results also do not support the use of omalizumab. Omalizumab was markedly less effective than
371 other biologics.

372 **Conclusion**

373 For patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing
374 exacerbations, without important differences in the effects of the three biologics. For patients with low
375 eosinophils, however, biologics, including tezepelumab, probably do not prevent exacerbations or
376 improve asthma control or lung function.

377 **Tables**

**Table 1: Trial characteristics**

| Trial | Registration | Male (%) | Age | Blood eosinophil (cells/uL) | IgE (IU/mL) | Oral corticosteroids (%) | Allergic asthma (%) | Interventions |
|---|---|---|---|---|---|---|---|---|
| **Ayres, 2004** | NR | 29.49 | 37.5 (omalizumab), 39.3 (standard care)§ | NR | 167 (omalizumab), NR (standard care)§ | NR | 100 | omalizumab, standard care |
| **Bardelas, 2012** | NCT00267202 | 33.58 | 41.3 | NR | 182.06 | 0 | 100 | omalizumab, placebo |
| **Bateman, 2017** | NCT01437735 | 42.3 | 44.9 | NR | NR | NR | 100 | fevivpiprant, placebo |
| **Bel, 2014 (SIRIUS)** | NCT01691508 | 45.19 | 50 | 240.22 | 115.53 | 100 | 45.92 | mepolizumab, placebo |
| **Bernstein, 2020 (Trial 1)** | NCT02452190 | 40.9 | 45 | 767.2 | NR | 6.5 | 67.5 | reslizumab, placebo |
| **Bernstein, 2020 (Trial 2)** | NCT02501629 | 34 | 54.3 | 500.1 | NR | 100 | 53 | reslizumab, placebo |
| **Bjermer, 2016** | NCT01270464 | 42 | 43.9 | 613.5 | NR | 0 | NR | reslizumab (0.3mg/kg), reslizumab (3mg/kg), placebo |
| **Bleecker, 2016 (SIROCCO)** | NCT01928771 | 33.89 | 48.8 | 370 (placebo), 390 (benralizumab (Q4wk)), 360 (benralizumab (Q8wk))§ | NR | 16.28 | 53.65 | benralizumab (Q4w), benralizumab (Q8w), placebo |
| **Boulet, 1997** | NR | 60 | 27 | NR | 410.78 | NR | 100 | omalizumab, placebo |
| **Brightling, 2020 (LUSTER 1)** | NCT02555683 | 35.84 | 50.36 | 320 (fevipiprant (150 mg)), 350 (fevipiprant (450)), 325 (placebo)§ | NR | NR | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| **Brightling, 2020 (LUSTER 2)** | NCT02563067 | 40.75 | 50.03 | 320 (fevipiprant (150 mg)), 340 (fevipiprant (450)), 300 (placebo)§ | NR | NR | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| **Busse, 2001** | NR | 40.9 | 39.1 | NR | 179.26 | 100 | 100 | omalizumab, placebo |
| **Castro, 2011** | NR | 40.5 | 45.35 | 500 | NR | 0 | 80 | omalizumab, placebo |
| **Castro, 2015 (Trial 1)** | NCT01287039 | 38 | 49 (placebo), 48 (reslizumab)§ | 660 | NR | 19 | NR | reslizumab, placebo |
| **Castro, 2015 (Trial 2)** | NCT01285323 | 36.5 | 48 (placebo), 48 (reslizumab)§ | 649 | NR | 12 | NR | reslizumab, placebo |
| **Castro, 2018 (LIBERTY ASTHMA QUEST 1)** | NR | 38.29 | 48 | 356.02 | 438.6 | 0 | NR | reslizumab, placebo |
| **Castro, 2018 (LIBERTY ASTHMA QUEST 2)** | NR | 35.85 | 47.87 | 364.46 | 426.1 | NR | NR | dupilimab, placebo |
| **Castro, 2021 (ZEAL 1)** | NCT03215758 | 35.8 | 47.9 | 348 | NR | NR | NR | dupilimab, placebo |
| **Castro, 2021 (ZEAL 2)** | NCT03226392 | 38.15 | 38.1 | 334.3 | NR | NR | NR | fevipiprant, placebo |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Chanez, 2010** | NCT00454051 | 38.7 | 47.4 | NR | 220.09 | 22.6 | 100 | fevipiprant, placebo |
| **Chupp, 2017 (MUSCA)** | NCT02281318 | 41.02 | 50.96 | 325.14 | NR | 23.77 | NR | omalizumab, placebo |
| **Corren, 2011** | NCT00495612 | 38 | 36.5 | NR | 208.89 | NR | 100 | mepolizumab, placebo |
| **Corren, 2016** | NCT01508936 | 36.1 | 44.9 | 280.2 | NR | 0 | NR | omalizumab every 2 weeks for 16 weeks, subcutaneous], placebo |
| **Corren, 2017 (PATHWAY)** | NCT02054130 | 34.36 | 51.55 | 370.48 | 409.96 | NR | NR | reslizumab, placebo |
| **Djukanovic, 2004** | NR | 46 | 26 (omalizumab), 26 (placebo)§ | NR | 155.5 (omalizumab), 141 (placebo)§ | NR | 100 | tezepelumab (70mg), tezepelumab (210mg), tezepelumab (280mg), placebo |
| **Erpenbeck, 2015** | NCT01253603 | 81.2 | 42 | NR | 166§ | 0 | 100 | omalizumab, placebo |
| **Ferguson, 2017** | NCT02322775 | 39 | 49.7 | 207.5 | NR | NR | 64 | fevipiprant, placebo |
| **FitzGerald, 2016 (CALIMA)** | NCT01914757 | 38 | 49.2 | 363.2 | NR | 9.2 | 63.3 | benralizumab, placebo |
| **Flood-Page, 2007** | NR | 44.2 | 36.31 | 365.48 | 161.5 (mepolizumab (750mg)), 203.0 (mepolizumab (250mg)), 178 (placebo)§ | NR | NR | benralizumab (Q4w), benralizumab (Q8w), placebo |
| **Gevaert, 2022 (THUNDER)** | NCT03681093 | 58.2 | 50.2 | NR | NR | NR | NR | mepolizumab (250mg), mepolizumab (750mg), placebo |
| **Gonem, 2016** | NCT01545726 | 50.82 | 50 | 280 | 414 (fevipiprant), 388 (placebo) | 23 | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| **Haldar, 2009** | ISRCTN75169762 | 52.46 | 49.05 | 336 | 186.82 | 55 | NR | fevipiprant, placebo |
| **Hanania, 2011** | NCT00314574 | 34.32 | 44.49 | NR | 176.91 | 18.75 | 100 | mepolizumab, placebo |
| **Harrison, 2020 (ANDHI)** | NCT03170271 | 39.18 | 52.78 | 390 (standard care), 390 (benralizumab)§ | NR | 19.66 | NR | omalizumab, standard care |
| **Hayashi, 2020** | UMIN000018777 | 37.5 | 53§ | 370§ | 169§ | 18.75 | 100 | benralizumab, placebo |
| **Holgate, 2004** | NR | 39.02 | 40.81 | NR | 266.26 | 0 | 100 | omalizumab, placebo |
| **Humbert, 2005 (INNOVATE)** | NR | 33.41 | 43.35 | NR | 193.59 | 21.72 | 100 | omalizumab, placebo |
| **Kelsen, 2021 (ZENYATTA)** | NCT02918019 | 33.9 | 51.9 | 246.7 | NR | NR | NR | omalizumab, placebo |
| **Kopp, 2018** | EUDRACT: 2005-003860-47 | 56.43 | 30 (omalizumab), 33 (placebo)§ | NR | 139.25 | NR | 100 | astegolimab (70mg, Q4w), astegolimab (120mg, Q4w), astegolimab (490mg, Q4w), |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | placebo |
| **Li, 2016** | NCT01202903 | 46.1 | 46.5 | NR | 275.4 | NR | 100 | omalizumab (dose not specified, every 2 or 4 weeks for 32 weeks, subcutaneous], placebo |
| **Menzies-Gow, 2021 (NAVIGATOR)** | NCT03347279 | 36.54 | 49.5 | 340 | 565 | 9.44 | 68.46 | omalizumab, placebo |
| **Nair, 2017 (ZONDA)** | NCT02075255 | 38.64 | 50.99 | 535 (placebo), 462 (benralizumab (Q4w)), 437 (benralizumab (Q8w))§ | NR | 100 | NR | tezepelumab, placebo |
| **Nowak, 2014** | NCT00768079 | 30 | 36.19 | 260 | NR | 100 | NR | benralizumab (Q4w), benralizumab (Q8w), placebo |
| **Ohta, 2009** | NCT00232050. | 45.71 | 49.01 | NR | 253.75 | 9.52 | 100 | benralizumab (0.3mg/kg), benralizumab (1mg/kg, one dose, intravenous], placebo |
| **Ortega, 2014** | NCT01691521 | 42.88 | 50 | 296.63 | 159.95 | 25 | 48.78 | omalizumab, placebo |
| **Panettieri, 2018 (STRATOS 1)** | NCT02161757 | 33.61 | 50.64 | 286 | NR | 0 | NR | mepolizumab (75mg), mepolizumab (100mg), placebo |
| **Panettieri, 2018 (STRATOS 2)** | NCT02194699 | 32.38 | 47.65 | 277.53 | NR | 0 | NR | tralokinumab (Q2w), tralokinumab (Q4w), placebo |
| **Panettieri, 2020 (SOLANA)** | NCT02869438 | 32.5 | 51.4 | 438.05 | NR | 6.9 | NR | Tralokinumab, placebo |
| **Park, 2016** | NCT01691508 | 36.89 | 52.72 | 682.91 | NR | NR | NR | benralizumab, placebo |
| **Pavord, 2012 (DREAM)** | NCT01000506 | 62.9 | 48.6 | 252.6 | NR | 30.4 | 50.5 | benralizumab (2mg), benralizumab (20mg), benralizumab (100mg), placebo |
| **Pineros, 2018 (MATERIAL)** | NCT01520051 | 25 | 23.5 | 350 | 303.12 | 0 | 100 | mepolizumab (75mg), mepolizumab (250mg), mepolizumab (750mg), placebo |
| **Piper, 2013** | NCT00873860 | 40.21 | 47.32 | NR | NR | 4.64 | 52 | mepolizumab, placebo |
| **Rabe, 2018 (LIBERTY ASTHMA VENTURE)** | NCT02528214 | 39.52 | 51.3 | 357 | NR | 100 | 56.67 | tralokinumab (150mg), tralokinumab (300mg), tralokinumab (600mg), placebo |
| **Rubin, 2012 (QUALITX)** | NR | 23.28 | 44.26 | NR | 228.76 | NR | 24.14 | dupilimab, placebo |
| **Russell, 2018 (MESOS)** | NCT02449473 | 45.57 | 48.62 | 284.81 | 476.28 | NR | NR | omalizumab, control (none) |
| **Soler, 2001** | NR | 49.1 | 39.5 | NR | 214.38 | 0 | 100 | tralokinumab, placebo |
| **Sverrild, 2021 (UPSTREAM)** | NCT02698501 | 42 | 41 | 214 | 102 | 0 | 65 | omalizumab, placebo |
| **Vignola, 2004 (SOLAR)** | NR | 44.94 | 38.39 | NR | NR | NR | 100 | tezepelumab, placebo |
| **Wechsler, 2021** | NCT03387852 | 36 | 49.1 | 372 | 419.3 | NR | 85 | omalizumab, placebo |
| **Wechsler, 2022 (SOURCE)** | NCT03406078 | 37 | 53.4 | 299.8 | 299.8 | 100 | 57 | itepekimab, itepekimab/dupilumab, dupilumab, placebo |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Wenzel, 2013** | NCT01312961 | 50 | 39.7 | 510 | 676.2 | NR | NR | tezepelumab, placebo |
| **Wenzel, 2016** | NCT01854047 | 37 | 48.6 | 347.46 | 435.05 | 0 | NR | dupilumab, placebo |
| **Zielen, 2011** | NR | 55.8 | 33.12 | NR | 662.92 | NR | 100 | dupilumab (200mg, Q4w), dupilumab (300mg, Q4w), dupilumab (200mg, Q2w), dupilumab (300mg, Q2w), placebo |

IgE: Immunoglobulin E

Data presented as mean unless specified with §. Data with § is median.

379 **Table 2**. Summary of findings table for network estimates presented in absolute risk difference per 1000 patients.

| GRADE recommendation | | | |
|---|---|---|---|
| High certainty | Definitely more beneficial than standard care | Definitely more harmful than standard care | Definitely no different than standard care |
| Moderate certainty | Probably more beneficial than standard care | Probably more harmful than standard care | Probably no different than standard care |
| Low certainty | May be more beneficial than standard care | May be more harmful than standard care | May be no different than standard care |
| Very low certainty | We are very uncertain | We are very uncertain | We are very uncertain |

| Drug | Asthma exacerbations | | ACQ | | FEV1 (L) | | Hospital admissions | Corticosteroid sparing | ADEL |
|---|---|---|---|---|---|---|---|---|---|
| *Eosinophils* | *≥ 300* | *< 300* | *≥ 300* | < 300 | *≥ 300* | < 300 | NA | NA | NA |
| *Baseline risk* | *470 per 1000* | | *NA* | | *NA* | | *137 per 1000* | *560 per 1000* | *19 per 1000* |
| *MCID/MID* | *20%* | | *-0.5* | | *0.1 L* | | *5%* | *20%* | *10%* |
| Tezepelumab | -329 (-366.6 to -272.6) | -173.9 (-277.3 to -23.5)‡ | -0.4 (-0.61 to -0.19)‡ | -0.23 (-0.36 to -0.09) | 0.24 (0.16 to 0.32) | 0.1 (0 to 0.19)¶ | -110.97 (-120.56 to -94.53)‡ | 33.6 (-72.8 to 168)¶ | -6.08 (-12.54 to 6.65) |
| Dupilumab | -319.6 (-357.2 to -272.6) | -112.8 (-225.6 to 51.7)‡ | -0.73 (-0.98 to -0.48)‡ | -0.2 (-0.42 to 0.02) | 0.25 (0.21 to 0.29) | 0.1 (0 to 0.2)¶ | -97.27 (-124.67 to -4.11)‡ | 274.4 (123.2 to 464.8)¶ | 0.57 (-10.26 to 24.7) |
| Mepolizumab | -211.5 (-258.5 to -155.1)‡ | | -0.33 (-0.51 to -0.15)‡ | 0.49 (0.01 to 0.97)‡ | 0.1 (0.04 to 0.15)‡ | | | 341.6 (39.2 to 789.6)‡ | -6.65 (-12.16 to 3.04) |
| Resliuzmab | -230.3 (-282 to -164.5)‡ | 371.3 (-188 to 2002.2)¶ | -0.28 (-0.44 to -0.11) | 0.12 (-0.09 to 0.33) | 0.19 (0.12 to 0.25) | 0.09 (-0.04 to 0.22)¶ | | 128.8 (-84 to 436.8)¶ | -6.65 (-11.21 to 0.38) |
| Benralizumab | -230.3 (-277.3 to -173.9)‡ | -145.7 (-263.2 to 37.6)‡ | -0.3 (-0.44 to -0.16) | -0.23 (-0.41 to -0.06) | 0.14 (0.11 to 0.18)‡ | 0.04 (-0.05 to 0.13)‡ | -17.81 (-41.1 to 10.96) | 431.2 (162.4 to 800.8)‡ | 12.35 (-3.99 to 46.55) |
| Astegolimab | -150.4 (-314.9 to 178.6) ¶ | -126.9 (-291.4 to 188) | | | | | | | |
| Fevipiprant | -89.3 (-183.3 to 42.3) | | -0.15 (-0.35 to 0.05) | | 0.05 (-0.01 to 0.12)‡ | | | | 0.19 (-6.65 to 10.83) |
| Tralokinumab | -70.5 (-178.6 to 75.2) | -89.3 (-244.4 to 173.9)‡ | -0.52 (-0.94 to -0.1)¶ | | | | -32.88 (-64.39 to 12.33)‡ | | 32.3 (8.55 to 76) |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Itepekimab | | | -0.46 (-0.8 to -0.12)‡* | | 0.18 (0 to 0.36)‡ | 0.09 (-0.1 to 0.28)¶ | | | |
| Itepekimab/dupilumab | | | -0.36 (-0.7 to -0.02)‡* | | 0.15 (-0.05 to 0.34)¶ | 0.05 (-0.14 to 0.24)¶ | | | |
| Omalizumab | -188 (-235 to 136.3)‡* | | -0.25 (-0.5 to 0.01)‡* | | 0.09 (0.02 to 0.16)‡* | | -84.94 (-105.49 to -47.95)‡ | 179.2 (84 to 285.6)‡ | 3.8 (-3.8 to 15.39)‡ |
| *$I^2$* | *36.30%* | *58%* | *50.10%* | *0%* | *38.80%* | *54.90%* | *25.20%* | *0%* | *5.70%* |

Note: CI = confidence interval, GRADE = Grading of Recommendations, Assessment, Development and Evaluation.

*No subgroup available, data from entire network.

All included estimates are network estimates. Negative values indicate fewer events and positive values indicate more events. Each node estimate is compared against placebo or standard care. The comparative effectiveness of a treatment on an outcome versus another treatment can be assessed by comparing respective cells. If the network estimate is not presented owing to lower certainty of the evidence, then direct comparisons need to be made using the network estimates provided in high certainty ( very confident that true effect lies close to that of effect estimate), moderate certainty (moderately confident in effect estimate; the true effect is likely to be close to effect estimate, but there is a possibility that it is substantially different), low certainty (confidence in the effect estimate is limited; true effect may be substantially different from the effect estimate) or very low certainty: (very little confidence in the effect estimate; true effect is likely to be substantially different from the effect estimate).

‡GRADE rating = imprecision.

¶GRADE rating = twice for imprecision.

††GRADE rating = inconsistency.

380 **References**


381 1. Global Asthma Network. Global Asthma Network Global Asthma Report 2018
382 www.globalasthmareport.org/ Date last updated: January 2018. Date last accessed: January 17, 2020.
383 2. Global Initiative for Asthma. (2002). Global strategy for asthma management and prevention.
384 Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute.
385 3. Mauer Y, Taliercio RM. Managing adult asthma: The 2019 GINA guidelines. Cleve Clin J Med.
386 2020;87(9):569-75.
387 4. Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting
388 the airway epithelium with next-generation biologics. European Respiratory Journal. 2020;56(5).
389 5. Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory
390 and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evid Based Med.
391 2022.
392 6. Hutton B, Catalá-López F, Moher D. [The PRISMA statement extension for systematic reviews
393 incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc). 2016;147(6):262-6.
394 7. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and
395 children. Cochrane Database Syst Rev. 2014(1):Cd003559.
396 8. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database
397 Syst Rev. 2017;9(9):Cd010834.
398 9. Menzies-Gow A, Steenkamp J, Singh S, Erhardt W, Rowell J, Rane P, et al. Tezepelumab
399 compared with other biologics for the treatment of severe asthma: a systematic review and indirect
400 treatment comparison. J Med Econ. 2022;25(1):679-90.
401 10. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a
402 systematic review and network meta-analysis. Respir Res. 2019;20(1):179.
403 11. Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-
404 analysis. Minerva Med. 2021;112(5):573-81.
405 12. Tejwani V, Chang HY, Tran AP, Naber JA, Gutzwiller FS, Winders TA, et al. A multistakeholder
406 Delphi consensus core outcome set for clinical trials in moderate-to-severe asthma (coreASTHMA). Ann
407 Allergy Asthma Immunol. 2021;127(1):116-22.e7.
408 13. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for
409 assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
410 14. Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. Antiviral drug treatment for
411 nonsevere COVID-19: a systematic review and network meta-analysis. Cmaj. 2022;194(28):E969-e80.
412 15. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted
413 systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.
414 Cochrane Database Syst Rev. 2019;10:Ed000142.
415 16. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models
416 for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7(1):80-93.
417 17. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study
418 effects in a network of interventions. Res Synth Methods. 2012;3(2):161-76.
419 18. Rücker G, Schwarzer G, Krahn U, König J, Schwarzer MG. Package 'netmeta'. Network Meta-
420 Analysis using Frequentist Methods (Version 07-0). 2015.
421 19. Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40-5.
422 20. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-
423 analysis in STATA. PloS one. 2013;8(10):e76654.
424 21. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et
425 al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J
426 Clin Epidemiol. 2018;93:36-44.

427 22. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging
428 consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.
429 23. Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al.
430 GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised
431 framework. Bmj. 2020;371:m3900.
432 24. Rogliani P, Calzetta L. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on
433 Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON
434 Studies. J Exp Pharmacol. 2022;14:1-5.
435 25. Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically
436 important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156).
437 26. Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M, et al. Asthma outcomes:
438 pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65-87.
439 27. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26:
440 informative statements to communicate the findings of systematic reviews of interventions. J Clin
441 Epidemiol. 2020;119:126-35.
442 28. Panettieri RA, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for
443 severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-
444 controlled, phase 3 clinical trials. Lancet respiratory medicine. 2018;6(7):511.
445 29. Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, et al. Effectiveness of fevipiprant in
446 reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3
447 randomised controlled trials. Lancet respiratory medicine. 2021;9(1):43.
448 30. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and
449 tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic
450 asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709.
451 31. Gevaert P, Bachert C, Maspero JF, Cuevas M, Steele D, Acharya S, et al. Phase 3b randomized
452 controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). Journal of Allergy
453 and Clinical Immunology. 2022.
454 32. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-Sparing
455 Effect of Benralizumab in Severe Asthma. New England journal of medicine. 2017;376(25):2448.
456 33. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-
457 immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe)
458 allergic asthma. Allergy. 2004;59(7):701.
459 34. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-
460 controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with
461 persistent allergic asthma. Journal of asthma. 2012;49(2):144.
462 35. Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and
463 impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms
464 for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised,
465 controlled, phase 3b trial. Lancet respiratory medicine. 2021;9(3):260.
466 36. Bateman ED, Guerreros AG, Brockhaus F, Holzhauer B, Pethe A, Kay RA, et al. Fevipiprant, an
467 oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled
468 corticosteroids. The european respiratory journal. 2017;50(2).
469 37. Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, et al. Effect of fixed-dose
470 subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and
471 corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3,
472 randomised, double-blind, placebo-controlled trials. Lancet respiratory medicine. 2020;8(5):461.

473 38. Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al.
474 Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind,
475 placebo-controlled, phase 3 trial. Lancet respiratory medicine. 2017;5(7):568.
476 39. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately
477 Controlled Asthma With Elevated Blood Eosinophil Levels: a Randomized Phase 3 Study. Chest.
478 2016;150(4):789.
479 40. Boulet LP, Chapman KR, ocirc, eacute, Kalra S, Bhagat R, et al. Inhibitory effects of an anti-IgE
480 antibody E25 on allergen-induced early asthmatic response. American journal of respiratory and critical
481 care medicine. 1997;155(6):1835.
482 41. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. American Journal
483 of Respiratory and Critical Care Medicine. 2001;164(8 II):S12-S7.
484 42. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-
485 interleukin-5 receptor &agr; monoclonal antibody, as add-on treatment for patients with severe,
486 uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3
487 trial. Lancet. 2016;388(10056):2128.
488 43. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for
489 inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre,
490 parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet respiratory medicine.
491 2015;3(5):355.
492 44. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly
493 controlled, eosinophilic asthma: a randomized, placebo-controlled study. American journal of
494 respiratory and critical care medicine. 2011;184(10):1125.
495 45. Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, et al. Omalizumab-induced
496 decrease of FcepsilonRI expression in patients with severe allergic asthma. Respiratory Medicine.
497 2010;104(11):1608-17.
498 46. Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, et al. Effects of omalizumab on changes in
499 pulmonary function induced by controlled cat room challenge. Journal of allergy and clinical
500 immunology. 2011;127(2):398.
501 47. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With
502 Poorly Controlled Asthma: effects Across a Broad Range of Eosinophil Counts. Chest. 2016;150(4):799.
503 48. Djukanovic R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al. Effect of treatment with
504 anti-IgE antibody (Omalizumab) on airway inflammation in mild atopic asthma. American thoracic
505 society 99th international conference. 2003:C082.
506 49. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe
507 eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (london,
508 england). 2012;380(9842):651.
509 50. Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B, et al. The oral CRTh2
510 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulmonary
511 pharmacology & therapeutics. 2016;39:54.
512 51. Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and Safety of
513 Itepekimab in Patients with Moderate-to-Severe Asthma. New England journal of medicine.
514 2021;385(18):1656.
515 52. Panettieri RA, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, et al. Onset of effect, changes in
516 airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab
517 for patients with severe eosinophilic asthma: phase iiib randomized, controlled trial (SOLANA). Journal
518 of asthma and allergy. 2020;13:115.

519 53. Sol, egrave, r M, Matz J, Townley R, Buhl R, et al. The anti-IgE antibody omalizumab reduces
520 exacerbations and steroid requirement in allergic asthmatics. The european respiratory journal.
521 2001;18(2):254.
522 54. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety
523 in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled
524 corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal
525 phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.
526 55. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent
527 asthma with elevated eosinophil levels. New England journal of medicine. 2013;368(26):2455.
528 56. Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, et al. Efficacy and safety of
529 fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind,
530 placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine. 2021;35.
531 57. Zielen S, Lieb A, De La Motte S, Wagner F, De Monchy J, Fuhr R, et al. Omalizumab protects
532 against allergen-induced bronchoconstriction in allergic (Immunoglobulin E-mediated) Asthma.
533 International archives of allergy and immunology. 2013;160(1):102.
534 58. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to
535 evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American
536 journal of respiratory and critical care medicine. 2007;176(11):1062.
537 59. Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, et al. Fevipiprant, a
538 prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre,
539 randomised, double-blind, parallel-group, placebo-controlled trial. Lancet respiratory medicine.
540 2016;4(9):699.
541 60. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and
542 exacerbations of refractory eosinophilic asthma. New England journal of medicine. 2009;360(10):973.
543 61. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe
544 allergic asthma inadequately controlled with standard therapy: a randomized trial. Annals of internal
545 medicine. 2011;154(9):573.
546 62. Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Kamide Y, et al. Omalizumab for Aspirin
547 Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A
548 Randomized Controlled Trial. American journal of respiratory and critical care medicine.
549 2020;201(12):1488.
550 63. Holgate ST, Chuchalin AG, eacute, bert J, ouml, tvall J, et al. Efficacy and safety of a recombinant
551 anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and experimental
552 allergy. 2004;34(4):632.
553 64. Humbert M, Beasley R, Ayres J, Slavin R, eacute, bert J, et al. Benefits of omalizumab as add-on
554 therapy in patients with severe persistent asthma who are inadequately controlled despite best
555 available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309.
556 65. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of
557 omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal
558 allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clinical and experimental allergy.
559 2009;39(2):271.
560 66. Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, et al. Omalizumab improves quality of life and
561 asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study.
562 Allergy, asthma & immunology research. 2016;8(4):319.
563 67. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and
564 Safety in Moderate-to-Severe Uncontrolled Asthma. New England journal of medicine.
565 2018;378(26):2486.

566 68. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of
567 Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England journal of medicine.
568 2018;378(26):2475.
569 69. Sabogal P, ntilde, eros YS, Bal SM, van de Pol MA, Dierdorp BS, et al. Anti-IL-5 in Mild Asthma
570 Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-
571 controlled, Double-Blind Study. American journal of respiratory and critical care medicine.
572 2019;199(4):508.
573 70. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab
574 treatment in patients with severe eosinophilic asthma. New England journal of medicine.
575 2014;371(13):1198.
576 71. Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, et al. Effect of
577 tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation
578 in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-
579 controlled phase 2 trial. Lancet respiratory medicine. 2018;6(7):499.
580 72. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of
581 mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe
582 eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group,
583 multicentre, phase 3b trial. Lancet respiratory medicine. 2017;5(5):390.
584 73. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in
585 Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384(19):1800-9.
586 74. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian
587 population with moderate-to-severe persistent asthma. Respirology. 2009;14(8):1156-65.
588 75. Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A Phase 2a Study of Benralizumab
589 for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol.
590 2016;169(3):135-45.
591 76. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of
592 benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. American
593 journal of emergency medicine. 2015;33(1):14.
594 77. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in Adults with
595 Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-46.
596 78. Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, et al. Effect of
597 omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian
598 study (QUALITX). Journal of asthma. 2012;49(3):288.
599 79. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study
600 of tralokinumab in moderate-to-severe asthma. The european respiratory journal. 2013;41(2):330.
601 80. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of
602 benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids
603 and long-acting &bgr;2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
604 Lancet (london, england). 2016;388(10056):2115.
605 81. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-
606 sparing effect of mepolizumab in eosinophilic asthma. New England journal of medicine.
607 2014;371(13):1189.
608 82. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a
609 questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-7.
610 83. Tan LD, Nguyen N, Alismail A, Castro M. Management of Uncontrolled Asthma: A Framework for
611 Novel and Legacy Biologic Treatments. J Asthma Allergy. 2022;15:875-83.

612 84. Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for Severe Asthma: Treatment-
613 Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract. 2019;7(5):1379-
614 92.
615 85. Adatia A, Wahab M, Satia I. Is tezepelumab more than just an anti-eosinophil drug? Eur Respir J.
616 2022;59(1).

617 **Figure 1.** Network diagrams for acute exacerbations with high and low eosinophils. Each node
618 represents a drug or drug combination that has been tested in trials; the size of the nodes is
619 proportional to the number of patients that have received that drug or drug combination; and the
620 thickness of the connecting lines is proportional to the number of trials.

621 **Figure 2.** Forest plots for exacerbations with high and low eosinophils .

622

A: Exacerbations among patients with eosinophilic asthma




B: Exacerbations among patients with low eosinophils




A: Exacerbations among patients with eosinophilic asthma
Drug
Risk Ratio
with 95% CI
Astegolimab
0.68 [ 0.33, 1.38]
Benralizumab
0.51 [ 0.41, 0.63]
Dupilumab
0.32 [ 0.24, 0.42]
Fevipiprant
0.81 [ 0.61, 1.09]
Mepolizumab
0.52 [ 0.43, 0.64]
Reslizumab
0.51 [ 0.40, 0.65]
Tezepelumab
0.30 [ 0.22, 0.42]
Tralokinumab
0.85 [ 0.62, 1.16]
Overall
Heterogeneity: $\tau^2$ = 0.0244, $I^2$ = 36.3%
0.25
0.5
1
Random-effects REML model


B: Exacerbations among patients with low eosinophils
Drug
Risk Ratio
with 95% CI
Astegolimab
0.73 [ 0.38, 1.40]
Benralizumab
0.69 [ 0.44, 1.08]
Dupilumab
0.76 [ 0.52, 1.11]
Reslizumab
1.78 [ 0.59, 5.33]
Tezepelumab
0.62 [ 0.41, 0.95]
Tralokinumab
0.82 [ 0.48, 1.38]
Overall
Heterogeneity: $\tau^2$ = 0.0804 $I^2$ = 58.00
0.5
1
2
4
Random-effects REML model